Abstract
Here is discussed the current scientific background for starting antiaggregation with Aspirin in the very initial phase of COVID-19 infection for preventing thrombotic infarctions before irreversible damage occurs in the target organs. Several authors are now describing the presence of endothelial cells into the bloodstream. This might indeed represent an epiphenomenon of the underlying mechanisms explaining the incidence of fatal systemic thrombotic complications. Antiaggregation with ASA would potentially have a significant prophylactic role, ideally before than anticoagulation and/or intensive care be the only options left: therefore dedicated trials should urgently be addressed to confirm this hypothesis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
